Health and Fitness Health and Fitness
Wed, January 5, 2011
[ Wed, Jan 05th 2011 ] - Market Wire
CEO of ARCA biopharma to Speak on Cardiovascular .. Medicine at Personalized Medicine Coalition Confe
[ Wed, Jan 05th 2011 ] - Market Wire
St. Jude Medical Announces Fourth Quarter and Full-Year 2010 Earnings Conference Call
[ Wed, Jan 05th 2011 ] - Market Wire
LabCorp is Scheduled to Present at the 29th Annual J.P. Morgan Healthcare Conference
[ Wed, Jan 05th 2011 ] - Market Wire
LifePoint Hospitals to Participate in 29th Annual J.P. Morgan Healthcare Conference
[ Wed, Jan 05th 2011 ] - Market Wire
Almirall and Forest Announce Positive Results fro .. of Aclidinium Bromide and the Phase IIb Studies w
[ Wed, Jan 05th 2011 ] - Market Wire
AngioDynamics Reports Fiscal 2011 Second Quarter Financial Results
[ Wed, Jan 05th 2011 ] - Market Wire
Alkermesa? Corporate Presentation to be Webcast at the JPMorgan Healthcare Conference
[ Wed, Jan 05th 2011 ] - Market Wire
Celgene ofrece nuevos datos sobre presentaciones normativas
[ Wed, Jan 05th 2011 ] - Market Wire
Celgene komt met update over het indienen van reglementaire aanvragen
[ Wed, Jan 05th 2011 ] - Market Wire
NeuroMetrix Announces New Strategic Direction
[ Wed, Jan 05th 2011 ] - Market Wire
Thermo Fisher Scientific to Present at the 29th A .. PMorgan Healthcare Conference on January 11, 2011
[ Wed, Jan 05th 2011 ] - Market Wire
InSite Vision Completes Patient Enrollment in ISV .. Study for Post-Surgical Ocular Pain and Swelling
[ Wed, Jan 05th 2011 ] - Market Wire
MannKind to Present at the JP Morgan 29th Annual HealthcareConference
[ Wed, Jan 05th 2011 ] - Market Wire
Kinetic Concepts, Inc. to Present at the 29th Annual J.P. Morgan Healthcare Conference
[ Wed, Jan 05th 2011 ] - Market Wire
Medisafe 1 Technologies Issues Letter to Shareholders
[ Wed, Jan 05th 2011 ] - Market Wire
PerkinElmer to Present at 29th Annual JP Morgan Healthcare Conference
[ Wed, Jan 05th 2011 ] - Market Wire
Teva Completes Acquisition of Th©ramex
Tue, January 4, 2011
[ Tue, Jan 04th 2011 ] - Market Wire
Law Office of Brodsky & Smith, LLC Announces Investigation of CPEX Pharmaceuticals, Inc.
[ Tue, Jan 04th 2011 ] - Market Wire
Finkelstein Thompson LLP Announces Investigation of CPEX Pharmaceuticals, Inc.
[ Tue, Jan 04th 2011 ] - Market Wire
Merck to Hold Fourth-Quarter 2010 Sales and Earnings Conference Call on Feb. 3
[ Tue, Jan 04th 2011 ] - Market Wire
The Law Office of Robbins Umeda LLP Announces an .. ion of CPEX Pharmaceuticals, Inc. by FCB I Holdin
[ Tue, Jan 04th 2011 ] - Market Wire
St. Jude Medical to Present at the 29th Annual J.P. Morgan Healthcare Conference
[ Tue, Jan 04th 2011 ] - Market Wire
The Law Firm of Levi & Korsinsky, LLP Launches an .. Breaches of Fiduciary Duty by the Board of CPEX P
[ Tue, Jan 04th 2011 ] - Market Wire
Briscoe Law Firm Investigates CPEX Pharmaceutical .. ders Concerning the Acquisition by Footstar, Inc.
[ Tue, Jan 04th 2011 ] - Market Wire
Illumina to Present at J.P. Morgan Healthcare Conference
[ Tue, Jan 04th 2011 ] - Market Wire
BioCryst to Present at J.P. Morgan Healthcare Conference
[ Tue, Jan 04th 2011 ] - Market Wire
Kiadis Pharma Signs License Agreement with Hospira to Commercialize ATIRa" in Europe and Asia
[ Tue, Jan 04th 2011 ] - Market Wire
Bio-Path Holdings to Present at the Biotech Showcasea" 2011 Conference
[ Tue, Jan 04th 2011 ] - Market Wire
ZIOPHARM Oncology Appoints Mark Thornton, M.D., P .. tive Vice President and Chief Development Officer
[ Tue, Jan 04th 2011 ] - Market Wire
AVEO Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference

AVEO Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference


Published on 2011-01-04 10:00:42 - Market Wire
  Print publication without navigation


CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at 10:00 a.m. (PST) at the Westin St. Francis Hotel in San Francisco. Mr. Ha-Ngoc is expected to present an overview of the company and updated financial guidance.

A live webcast of AVEOa™s presentation can be accessed by visiting the investors section of the companya™s website at investor.aveopharma.com. A replay of the webcast will be archived on the AVEO website for two weeks following the presentation.

About AVEO

AVEO Pharmaceuticals (NASDAQ: AVEO) is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies to impact patientsa™ lives. The companya™s lead product candidate, tivozanib, is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in patients with advanced renal cell carcinoma, as well as additional clinical studies in other solid tumor types. AVEOa™s second most advanced product candidate, AV-299, is a potent, functional anti-HGF/c-MET pathway antibody that is currently in Phase 2 clinical development. AVEOa™s proprietary Human Response Platforma" offers the company a unique advantage in cancer drug development and has provided a discovery engine for high-value therapeutic targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets including HGF, ErbB3, RON, Notch and FGFR. For more information, please visit the companya™s website at www.aveopharma.com.

Contributing Sources